



UNIVERSITY: University of Navarre (UNAV)

WIT PROGRAMME'S RESEARCH LINE NAME: Hematology: advanced therapies and diagnostic innovation

DOCTORAL PROGRAMME: Doctoral Program of applied medicine and biomedicine <https://en.unav.edu/web/doctoral-program-of-applied-medicine-and-biomedicine>

COMPLETE DESCRIPTION OF THE LINE

Multiple myeloma (MM) represents a unique model to investigate circulating tumor cells (CTCs) and the mechanisms of chemoresistance through minimal residual disease (MRD) clones. While de facto characterization of these highly-professional clones responsible for disease dissemination and dramatic relapses after optimal response to therapy has been insurmountable due to the technical challenge of detecting and isolating rare tumor cells, our innovative methodological approach based on integrated next-generation flow cytometry and sequencing provides new solutions. Thus, our main objective is to identify new therapeutic targets to overcome disease dissemination and chemoresistance by studying the genomic landscape of CTCs and MRD clones.

RESEARCH GROUP NAME: Myeloma and other gammopathies

COORDINATOR:

Apellidos, Nombre: Paiva, Bruno

<https://orcid.org/0000-0003-1977-3815>

Departamento: Departamento de Hematología y Hemoterapia / CIMA LAB Diagnostics. Clínica Universidad de Navarra



Email: bpaiva@unav.es

Telefono: +34948194700

MEMBERS OF THE LINE RESEARCH:

Jesús San Miguel

Bruno Paiva

Paula Rodríguez

Aintzane Zabaleta

Sarai Sarvide

Ibai Goicoechea

Juan José Garcés

Cristina Pérez

Caratina Da Silva

Catia Simoes

Asara del Mar Rodríguez

Rosalinda Termini

Camila Guerrero

ANOTHER RESEARCH LINES OF THE GROUP

We prioritize our research in monoclonal gammopathies such as multiple myeloma (MM), light-chain amyloidosis (AL) or Waldenstöm's Macroglobulinemia (WM), and such research can be categorized into five well-defined areas: 1) Pathogenesis of MM, AL and WM; 2) Risk of transformation in non-IgM and IgM MGUS; 3) Circulating tumor cells (CTCs); 4) Minimal residual disease (MRD); and 5) 5. Immune monitoring



- Entities involved in research lines and contact person:
 - ✓ Academic entities: University of Navarra
 - ✓ Industrial entities: Becton Dickinson, BMS-Celgene, Janssen, Miltenyi, Sanofi, Roche, Takeda
- Group review

The Myeloma Group at Universidad de Navarra is a multidisciplinary and motivated research group that builds upon the legacy of Prof. San Miguel in the field of hematological malignancies and particularly, multiple myeloma (MM). During the last five years, we have published over 170 manuscripts in peer-reviewed Journals, achieving a total impact factor of 2,170 (average impact factor of 12.8 per manuscript). Our investigators commonly present new scientific abstracts in the most important American and European meetings, and are invited speakers in more than 100 meetings per year.

- Link of the group to the “Portal of scientific production”
<https://cima.cun.es/investigacion/programas-investigacion/programa-investigacion-hemato-oncologia>